Skip to main content

Advertisement

SpringerLink
Log in

Association between the RAGE G82S polymorphism and Alzheimer’s disease

  • Dementias - Original Article
  • Published:
Journal of Neural Transmission Aims and scope Submit manuscript

Abstract

The receptor for advanced glycation end products (RAGE) is associated with several pathological states including Alzheimer’s disease (AD) pathology, while its soluble form (sRAGE) acts as a decoy receptor. We have tested for association of AD with a functional single-nucleotide polymorphism (SNP) in the RAGE gene (G82S; rs2070600), a SNP associated with increased ligand affinity of RAGE. Analysis of a Chinese cohort (276 cases; 254 controls) showed a higher prevalence of the RAGE 82S allele and GS + SS genotype in the patients [82S vs. 82G: P = 0.017, odds ratio (OR) = 1.431; GS + SS vs. GG: P = 0.025, OR = 1.490]. Further stratification analysis revealed that the association of the RAGE G82S polymorphism with AD was significant in early onset AD stratum. Moreover, plasma sRAGE levels were lower in AD than in normal elderly controls, and the presence of the risk allele was associated with further plasma sRAGE reduction and a fast cognitive deterioration. The present study provides preliminary evidence that the RAGE G82S variant is involved in genetic susceptibility to AD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Arancio O, Zhang HP, Chen X, Lin C, Trinchese F, Puzzo D, Liu S, Hegde A, Yan SF, Stern A, Luddy JS, Lue LF, Walker DG, Roher A, Buttini M, Mucke L, Li W, Schmidt AM, Kindy M, Hyslop PA, Stern DM, Du Yan SS (2004) RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. EMBO J 23:4096–4105

    Article  CAS  PubMed  Google Scholar 

  • Cacquevel M, Lebeurrier N, Chéenne S, Vivien D (2004) Cytokines in neuroinflammation and Alzheimer’s disease. Curr Drug Targets 5:529–534

    Article  CAS  PubMed  Google Scholar 

  • Catalano M, Cortelazzo A, Santi R, Contino L, Demicheli M, Yilmaz Y, Zorzetto M, Campo I, Lanati N, Emanuele E (2008) The Pro12Ala polymorphism of peroxisome proliferator-activated receptor-gamma2 gene is associated with plasma levels of soluble RAGE (receptor for advanced glycation endproducts) and the presence of peripheral arterial disease. Clin Biochem 41:981–985

    Article  CAS  PubMed  Google Scholar 

  • Chaney MO, Stine WB, Kokjohn TA, Kuo YM, Esh C, Rahman A, Luehrs DC, Schmidt AM, Stern D, Yan SD, Roher AE (2005) RAGE and amyloid beta interactions: atomic force microscopy and molecular modeling. Biochim Biophys Acta 1741:199–205

    CAS  PubMed  Google Scholar 

  • Chen X, Walker DG, Schmidt AM, Arancio O, Lue LF, Yan SD (2007) RAGE: a potential target for Abeta-mediated cellular perturbation in Alzheimer’s disease. Curr Mol Med 7:735–742

    Article  CAS  PubMed  Google Scholar 

  • Convit A, Wolf OT, Tarshish C, de Leon MJ (2003) Reduced glucose tolerance is associated with poor memory performance and hippocampal atrophy among normal elderly. Proc Natl Acad Sci USA 100:2019–2022

    Article  CAS  PubMed  Google Scholar 

  • Doody RS, Massman P, Dunn JK (2001) A method for estimating progression rates in Alzheimer disease. Arch Neurol 58:449–454

    Article  CAS  PubMed  Google Scholar 

  • Emanuele E, D’Angelo A, Tomaino C, Binetti G, Ghidoni R, Politi P, Bernardi L, Maletta R, Bruni AC, Geroldi D (2005) Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia. Arch Neurol 62:1734–1736

    Article  PubMed  Google Scholar 

  • Ertekin-Taner N (2007) Genetics of Alzheimer’s disease: a centennial review. Neurol Clin 25:611–667, v

    Google Scholar 

  • Ghidoni R, Benussi L, Glionna M, Franzoni M, Geroldi D, Emanuele E, Binetti G (2008) Decreased plasma levels of soluble receptor for advanced glycation end products in mild cognitive impairment. J Neural Transm 115:1047–1050

    Article  CAS  PubMed  Google Scholar 

  • Go RCP, Collins JS, Watson B Jr, Vanichanan CJ, Acton RT, Blacker D, Albert MS, Tanzi R, McInnis MG, Bassett SS, Campbell D, Perry RT (1998) Evidence for linkage to 6p21.3 in Alzheimer disease families containing APOE E4/E4 genotypes. Am J Hum Genet 634:A291

    Google Scholar 

  • Gu H, Yang L, Sun Q, Zhou B, Tang N, Cong R, Zeng Y, Wang B (2008) Gly82Ser polymorphism of the receptor for advanced glycation end products is associated with an increased risk of gastric cancer in a Chinese population. Clin Cancer Res 14:3627–3632

    Article  CAS  PubMed  Google Scholar 

  • Ho L, Qin W, Pompl PN, Xiang Z, Wang J, Zhao Z, Peng Y, Cambareri G, Rocher A, Mobbs CV, Hof PR, Pasinetti GM (2004) Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer’s disease. FASEB J 18:902–904

    CAS  PubMed  Google Scholar 

  • Hofmann MA, Drury S, Hudson BI, Gleason MR, Qu W, Lu Y, Lalla E, Chitnis S, Monteiro J, Stickland MH, Bucciarelli LG, Moser B, Moxley G, Itescu S, Grant PJ, Gregersen PK, Stern DM, Schmidt AM (2002) RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response. Genes Immun 3:123–135

    Article  CAS  PubMed  Google Scholar 

  • Hudson BI, Stickland MH, Grant PJ (1998) Identification of polymorphisms in the receptor for advanced glycation end products (RAGE) gene: prevalence in type 2 diabetes and ethnic groups. Diabetes 47:1155–1157

    Article  CAS  PubMed  Google Scholar 

  • Hudson BI, Stickland MH, Futers TS, Grant P (2001) Effects of novel polymorphisms in the RAGE gene on transcriptional regulation and their association with diabetic retinopathy. Diabetes 50:1505–1511

    Article  CAS  PubMed  Google Scholar 

  • Jang Y, Kim JY, Kang SM, Kim JS, Chae JS, Kim OY, Koh SJ, Lee HC, Ahn CW, Song YD, Lee JH (2007) Association of the Gly82Ser polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating levels of soluble RAGE and inflammatory markers in nondiabetic and nonobese Koreans. Metabolism 56:199–205

    Article  CAS  PubMed  Google Scholar 

  • LaFerla FM, Oddo S (2005) Alzheimer’s disease: Abeta, tau and synaptic dysfunction. Trends Mol Med 11:170–176

    Article  CAS  PubMed  Google Scholar 

  • Lambert JC, Mann D, Harris J, Araria-Goumidi L, Chartier-Harlin MC, Cottel D, Iwatsubo T, Amouyel P, Lendon C (2004) Association study of Notch 4 polymorphisms with Alzheimer’s disease. J Neurol Neurosurg Psychiatry 75:377–381

    Article  PubMed  Google Scholar 

  • Lue LF, Walker DG, Brachova L, Beach TG, Rogers J, Schmidt AM, Stern DM, Yan SD (2001) Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer’s disease: identification of a cellular activation mechanism. Exp Neurol 171:29–45

    Article  CAS  PubMed  Google Scholar 

  • Lue LF, Yan SD, Stern DM, Walker DG (2005) Preventing activation of receptor for advanced glycation endproducts in Alzheimer’s disease. Curr Drug Targets CNS Neurol Disord 4:249–266

    Article  CAS  PubMed  Google Scholar 

  • Ma SL, Tang NL, Tam CW, Lui VW, Suen EW, Chiu HF, Lam LC (2008) Association between HLA-A alleles and Alzheimer’s disease in a southern Chinese community. Dement Geriatr Cogn Disord 26:391–397

    Article  CAS  PubMed  Google Scholar 

  • Matsui T, Yamagishi S, Ueda S, Nakamura K, Imaizumi T, Takeuchi M, Inoue H (2007) Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-induced monocyte chemoattractant protein-1 expression in mesangial cells through downregulation of receptor for AGEs via peroxisome proliferator-activated receptor-gamma activation. J Int Med Res 35:482–489

    CAS  PubMed  Google Scholar 

  • McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology 34:939–944

    CAS  PubMed  Google Scholar 

  • Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, Elliston K, Stern D, Shaw A (1992) Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 267:14998–15004

    CAS  PubMed  Google Scholar 

  • Nozaki I, Watanabe T, Kawaguchi M, Akatsu H, Tsuneyama K, Yamamoto Y, Ohe K, Yonekura H, Yamada M, Yamamoto H (2007) Reduced expression of endogenous secretory receptor for advanced glycation endproducts in hippocampal neurons of Alzheimer’s disease brains. Arch Histol Cytol 70:279–290

    Article  CAS  PubMed  Google Scholar 

  • Onyango IG, Tuttle JB, Bennett JP Jr (2005) Altered intracellular signaling and reduced viability of Alzheimer’s disease neuronal cybrids is reproduced by beta-amyloid peptide acting through receptor for advanced glycation end products (RAGE). Mol Cell Neurosci 29:333–343

    Article  CAS  PubMed  Google Scholar 

  • Origlia N, Righi M, Capsoni S, Cattaneo A, Fang F, Stern DM, Chen JX, Schmidt AM, Arancio O, Yan SD, Domenici L (2008) Receptor for advanced glycation end product-dependent activation of p38 mitogen-activated protein kinase contributes to amyloid-beta-mediated cortical synaptic dysfunction. J Neurosci 28:3521–3530

    Article  CAS  PubMed  Google Scholar 

  • Park IH, Yeon SI, Youn JH, Choi JE, Sasaki N, Choi IH, Shin JS (2004) Expression of a novel secreted splice variant of the receptor for advanced glycation end products (RAGE) in human brain astrocytes and peripheral blood mononuclear cells. Mol Immunol 40:1203–1211

    Article  CAS  PubMed  Google Scholar 

  • Prevost G, Fajardy I, Fontaine P, Danze PM, Besmond C (1999) Human RAGE GLY82SER dimorphism and HLA class II DRB1-DQA1-DQB1 haplotypes in type 1 diabetes. Eur J Immunogenet 26:343–348

    Article  CAS  PubMed  Google Scholar 

  • Pullerits R, Bokarewa M, Dahlberg L, Tarkowski A (2005) Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control. Arthritis Res Ther 7:R817–R824

    Article  CAS  PubMed  Google Scholar 

  • Schlueter C, Hauke S, Flohr AM, Rogalla P, Bullerdiek J (2003) Tissue-specific expression patterns of the RAGE receptor and its soluble forms—a result of regulated alternative splicing? Biochim Biophys Acta 1630:1–6

    CAS  PubMed  Google Scholar 

  • Schmidt AM, Yan SD, Yan SF, Stern DM (2000) The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta 1498:99–111

    Article  CAS  PubMed  Google Scholar 

  • Schmidt AM, Yan SD, Yan SF, Stern DM (2001) The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 108:949–955

    CAS  PubMed  Google Scholar 

  • Stranahan AM, Norman ED, Lee K, Cutler RG, Telljohann RS, Egan JM, Mattson MP (2008) Diet-induced insulin resistance impairs hippocampal synaptic plasticity and cognition in middle-aged rats. Hippocampus 18:1085–1088

    Article  PubMed  Google Scholar 

  • Sturchler E, Galichet A, Weibel M, Leclerc E, Heizmann CW (2008) Site-specific blockade of RAGE-Vd prevents amyloid-beta oligomer neurotoxicity. J Neurosci 28:5149–5158

    Article  CAS  PubMed  Google Scholar 

  • Sugaya K, Fukagawa T, Matsumoto K, Mita K, Takahashi E, Ando A, Inoko H, Ikemura T (1994) Three genes in the human MHC class III region near the junction with the class II: gene for receptor of advanced glycosylation end products, PBX2 homeobox gene and a notch homolog, human counterpart of mouse mammary tumor gene int-3. Genomics 23:408–419

    Article  CAS  PubMed  Google Scholar 

  • Takeuchi M, Kikuchi S, Sasaki N, Suzuki T, Watai T, Iwaki M, Bucala R, Yamagishi S (2004) Involvement of advanced glycation end-products (AGEs) in Alzheimer’s disease. Curr Alzheimer Res 1:39–46

    Article  CAS  PubMed  Google Scholar 

  • Tanaka N, Yonekura H, Yamagishi S, Fujimori H, Yamamoto Y, Yamamoto H (2000) The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells. J Biol Chem 275:25781–25790

    Article  CAS  PubMed  Google Scholar 

  • Watson GS, Craft S (2006) Insulin resistance, inflammation, and cognition in Alzheimer’s disease: lessons for multiple sclerosis. J Neurol Sci 245:21–33

    Article  CAS  PubMed  Google Scholar 

  • Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A, Slattery T, Zhao L, Nagashima M, Morser J, Migheli A, Nawroth P, Stern D, Schmidt AM (1996) RAGE and amyloid-beta peptide neurotoxicity in Alzheimer’s disease. Nature 382:685–691

    Article  CAS  PubMed  Google Scholar 

  • Yan SD, Zhu H, Fu J, Yan SF, Roher A, Tourtellotte WW, Rajavashisth T, Chen X, Godman GC, Stern D, Schmidt AM (1997) Amyloid-beta peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease. Proc Natl Acad Sci USA 94:5296–5301

    Article  CAS  PubMed  Google Scholar 

  • Yoshida T, Yamagishi S, Nakamura K, Matsui T, Imaizumi T, Takeuchi M, Koga H, Ueno T, Sata M (2006) Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation. Diabetologia 49:3094–3099

    Article  CAS  PubMed  Google Scholar 

  • Yoshioka K, Yoshida T, Takakura Y, Umekawa T, Kogure A, Toda H, Yoshikawa T (2005) Association study of G1704T and G82S polymorphisms of RAGE gene for microalbuminuria in Japanese type 2 diabetic patients. Metabolism 54:488–491

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by the Natural Science Foundation of Guangdong Province, China (No 7009941) and Natural Science Foundation of Heilongjiang Province, China (No D2007-14).

Conflict of interest statement

The authors have no actual or potential conflicts of interest related to this manuscript. Appropriate approval and procedures were used concerning human subjects.

Author information

Authors and Affiliations

  1. Department of Neurology, Affiliated Hospital of Guangdong Medical College, 524001, Zhanjiang, China

    Keshen Li & Bin Zhao

  2. Institute of Biomedical Engineering, Harbin Engineering University, 150001, Harbin, China

    Keshen Li

  3. Department of Neurology, The First Affiliated Hospital, Harbin Medical University, 150001, Harbin, China

    Dawei Dai & Lifen Yao

  4. Department of Molecular Epidemiology, Harbin Medical University, 150081, Harbin, China

    Songpo Yao & Binyou Wang

  5. Department of Public Health, Jiamusi University, 154007, Jiamusi, China

    Songpo Yao

  6. Laboratory for Medical Genetics, Institute of Geriatrics, Beijing Hospital, Ministry of Health, 100730, Beijing, China

    Ze Yang

Authors
  1. Keshen Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dawei Dai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bin Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lifen Yao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Songpo Yao
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Binyou Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ze Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Bin Zhao or Lifen Yao.

Additional information

K. Li and D. Dai have contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Li, K., Dai, D., Zhao, B. et al. Association between the RAGE G82S polymorphism and Alzheimer’s disease. J Neural Transm 117, 97–104 (2010). https://doi.org/10.1007/s00702-009-0334-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00702-009-0334-6

Keywords

Search

Navigation